Journal of Thrombosis and Thrombolysis

, Volume 25, Issue 1, pp 85–90 | Cite as

Managing anticoagulant related coagulopathy

Article

References

  1. 1.
    Flaherty ML, Kissela B, Woo D et al (2007) The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology 68(2):116–121PubMedCrossRefGoogle Scholar
  2. 2.
    Koo S, Kucher N, Nguyen PL, Fanikos J, Marks PW, Goldhaber SZ (2004) The effect of excessive anticoagulation on mortality and morbidity in hospitalized patients with anticoagulant-related major hemorrhage. Arch Intern Med 164(14):1557–1560PubMedCrossRefGoogle Scholar
  3. 3.
    Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S (2004) Hemorrhagic complications of anticoagulant treatment: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126(3 Suppl):287S–310SPubMedCrossRefGoogle Scholar
  4. 4.
    Hylek EM, Heiman H, Skates SJ, Sheehan MA, Singer DE (1998) Acetaminophen and other risk factors for excessive warfarin anticoagulation. Jama 279(9):657–662PubMedCrossRefGoogle Scholar
  5. 5.
    Hart RG, Pearce LA, Aguilar MI (2007) Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146(12):857–867PubMedGoogle Scholar
  6. 6.
    Beyth RJ, Quinn LM, Landefeld CS (1998) Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 105(2):91–99PubMedCrossRefGoogle Scholar
  7. 7.
    Gage BF, Yan Y, Milligan PE et al (2006) Clinical classification schemes for predicting hemorrhage: results from the national registry of atrial fibrillation (NRAF). Am Heart J 151(3):713–719PubMedCrossRefGoogle Scholar
  8. 8.
    Hylek EM, Chang YC, Skates SJ, Hughes RA, Singer DE (2000) Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med 160(11):1612–1617PubMedCrossRefGoogle Scholar
  9. 9.
    Kearon C, Ginsberg JS, Kovacs MJ et al (2003) Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 349(7):631–639PubMedCrossRefGoogle Scholar
  10. 10.
    Ridker PM, Goldhaber SZ, Danielson E et al (2003) Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 348(15):1425–1434PubMedCrossRefGoogle Scholar
  11. 11.
    Kearon C (2004) Long-term management of patients after venous thromboembolism. Circulation 110(9 Suppl 1):I10–18PubMedCrossRefGoogle Scholar
  12. 12.
    DeLoughery TG (2005) Venous thromboembolism in the ICU and reversal of bleeding on anticoagulants. Crit Care Clin 21(3):497–512PubMedCrossRefGoogle Scholar
  13. 13.
    Grand’Maison ACA, Geerts WH (2005) Anticoagulant use in patients with chronic renal impairment. Am J Cardiovasc Drugs 5(5):291–305PubMedCrossRefGoogle Scholar
  14. 14.
    Thorevska N, Amoateng-Adjepong Y, Sabahi R et al (2004) Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin. Chest 125(3):856–863PubMedCrossRefGoogle Scholar
  15. 15.
    Aguilar MI, Hart RG, Kase CS et al (2007) Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clin Proc 82(1):82–92PubMedCrossRefGoogle Scholar
  16. 16.
    Mayer SA, Brun NC, Begtrup K et al (2005) Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 352(8):777–785PubMedCrossRefGoogle Scholar
  17. 17.
    Dager WE, King JH, Regalia RC et al (2006) Reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated factor VII in patients receiving warfarin. Pharmacotherapy 26(8):1091–1098PubMedCrossRefGoogle Scholar
  18. 18.
    Lisman T, De Groot PG (2003) Mechanism of action of recombinant factor VIIa. J Thromb Haemost 1(6):1138–1139PubMedCrossRefGoogle Scholar
  19. 19.
    Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E (2004) The pharmacology and management of the vitamin K antagonists: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126(3 Suppl):204S–233SPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.Associate Professor of Medicine, Department of General Internal MedicineCleveland Clinic Lerner College of MedicineClevelandUSA

Personalised recommendations